Merck–SciBrunch SPR2015: A $400M Preclinical Bet | Lucid Diligence Brief

This Lucid Diligence Brief examines Merck’s licensing deal for SciBrunch’s SPR2015 and the clinical, competitive and development questions around the preclinical KRAS G12D program.

Professional audiences only. Not investment research or advice. UK readers: for persons under Article 19(5) or Article 49(2)(a)–(d) of the Financial Promotion Order 2005. Others should not act on this communication.

Dive deeper

Seven questions, 60-second thesis frame.

What changed: Merck Licenses SciBrunch’s SPR2015 for Up to $2.13B

On 28 Sep 2026, Merck agreed to license worldwide development, manufacturing and commercialization rights to SciBrunch Therapeutics’ SPR2015, a preclinical oral molecular-glue KRAS G12D (ON) inhibitor. SciBrunch receives $400 million upfront, with total potential consideration of $2.13 billion, implying up to $1.73 billion of additional milestones. The transaction has closed. (Merck/SciBrunch announcement, Reuters)

The unusually important qualifier is preclinical. SPR2015 has not yet produced human efficacy or safety data, while other KRAS G12D programs have already reached clinical development. (Reuters)

60-Second Thesis: Merck Bets on Preclinical KRAS G12D Differentiation

This is a $400 million upfront bet on preclinical differentiation, not clinical validation. SPR2015 forms a ternary complex with cyclophilin A and KRAS G12D and covalently targets the active, GTP-bound state. SciBrunch’s AACR 2026 work reported tumor regression in PDAC/NSCLC mouse models and a 64.7% ORR and 94.1% DCR across a CRC CDX/PDX model panel, alongside favorable 28-day rodent tolerability. (AACR SPR2015 abstract)

The diligence question is whether those properties survive translation into humans strongly enough to compensate for SPR2015’s later start. Zoldonrasib has already shown a 52% confirmed ORR in 27 efficacy-evaluable previously treated KRAS G12D NSCLC patients, while VS-7375 is also producing early human activity across PDAC, CRC and NSCLC. (AACR zoldonrasib clinical data, Verastem VS-7375 clinical update)

Seven Diligence Questions for the Merck–SciBrunch SPR2015 Deal

Clinical

• Can SPR2015 reproduce its preclinical CRC differentiation in humans? CRC may be the most informative test. SciBrunch says existing G12D inhibitors have yet to demonstrate clinically meaningful CRC monotherapy efficacy, while SPR2015 produced responses across its CRC xenograft panel. (AACR SPR2015 abstract)
• What human exposure is required for sustained KRAS G12D engagement, and is that exposure tolerable? Mouse PK/PD and 28-day rodent toxicology are encouraging, but they do not establish a human therapeutic window. (AACR SPR2015 abstract)

Payer or Access

• Which indication offers a clinically meaningful differentiation that could support premium targeted-therapy access? PDAC, CRC and NSCLC are listed development opportunities, but their standards of care and competitive benchmarks differ materially. (SciBrunch pipeline)
• Will SPR2015 ultimately need combinations to generate differentiated outcomes? If combinations with chemotherapy, EGFR blockade or immunotherapy become necessary, efficacy may improve while toxicity, cost and attribution become harder.

Ops or Adoption

• Can Merck move a preclinical asset fast enough to narrow the development gap? SciBrunch’s AACR abstract said SPR2015 was IND-enabling and expected to enter Phase 1 by end-2026. (AACR SPR2015 abstract)

Competitive

• Is SPR2015 genuinely differentiated from zoldonrasib and ON/OFF approaches such as VS-7375? Zoldonrasib already has human efficacy data and has progressed into pivotal development in PDAC, while VS-7375 is clinically testing monotherapy and combinations. (Revolution Medicines clinical update, Verastem pipeline)

Team or Cap table

• What did Merck see that justified $400 million upfront before first-in-human data? The disclosed economics make this a useful proxy for Merck’s conviction in SPR2015’s chemistry and preclinical package, but the milestone structure, royalties and indication-specific economics have not been publicly detailed. (Merck/SciBrunch announcement, Reuters)

Merck–SciBrunch SPR2015 Deal: Key Risks and Red Flags

• Human translation fails. The headline CRC ORR is from mouse CDX/PDX models, not patients. A weak Phase 1 pharmacodynamic or response signal would directly challenge the differentiation thesis. (AACR SPR2015 abstract)
• Competitive time compresses. Zoldonrasib is already generating human NSCLC data and moving into pivotal PDAC development, while SPR2015 remains preclinical. (AACR zoldonrasib clinical data)
• The molecular-glue advantage does not translate into therapeutic-index advantage. Strong CypA binding, target engagement and xenograft activity matter only if clinically achievable exposure produces durable responses without dose-limiting toxicity. (AACR SPR2015 abstract)

What to Watch Next: SPR2015 First-in-Human Development

IND/CTA clearance and first patient dosed, expected around end-2026 based on SciBrunch’s April AACR disclosure. Watch particularly for starting dose, escalation design, tumor cohorts, PK/PD markers and whether Merck prioritizes CRC as an early differentiation test. (AACR SPR2015 abstract)

FAQ: Merck–SciBrunch SPR2015 Deal

What exactly changed with Merck’s SPR2015 licensing announcement on 28 Sep 2026?

Merck acquired exclusive worldwide rights to develop, manufacture and commercialize SPR2015 from SciBrunch Therapeutics. SciBrunch receives $400 million upfront and can receive additional milestones taking total potential consideration to $2.13 billion. (Merck/SciBrunch announcement, Reuters)

How advanced was SPR2015 when Merck licensed it on 28 Sep 2026?

SPR2015 was still preclinical and had not entered human testing. SciBrunch’s AACR 2026 abstract described it as IND-enabling and projected Phase 1 entry by the end of 2026. (AACR abstract 5978, Reuters)

What efficacy evidence supported Merck’s SPR2015 deal announced on 28 Sep 2026?

SciBrunch reported nanomolar activity in KRAS G12D-mutant cell lines and tumor regression in mouse PDAC and NSCLC models. In more than 15 CRC CDX/PDX models, the company reported a 64.7% ORR and 94.1% DCR, but these are preclinical animal-model results and should not be interpreted as patient response rates. (AACR SPR2015 abstract)

What safety issue matters most after Merck’s SPR2015 announcement on 28 Sep 2026?

Human safety remains unknown because SPR2015 has not yet entered clinical testing. SciBrunch reported favorable in-vitro safety and tolerability in a 28-day rodent repeat-dose study, so the critical next evidence is whether clinically useful human exposure can be achieved without dose-limiting toxicity. (AACR SPR2015 abstract)

How competitive is SPR2015 following Merck’s 28 Sep 2026 licensing deal?

The field is already clinically competitive. Zoldonrasib has reported human KRAS G12D NSCLC activity and is advancing pivotal PDAC development, while VS-7375 is in Phase 1/2 testing across KRAS G12D-mutant tumors. (AACR zoldonrasib data, Revolution Medicines PDAC update, Verastem VS-7375 update)

Publisher / Disclosure

Publisher: LucidQuest Ventures Ltd. Produced: 28 Sep 2026, 13:12 London. Purpose: general and impersonal information. Not investment research or advice, no offer or solicitation, no suitability assessment. UK: directed at investment professionals under Article 19(5) and certain high-net-worth entities under Article 49(2)(a)–(d) of the Financial Promotion Order 2005. Others should not act on this. Sources and accuracy: public sources believed reliable, provided “as is,” may change without notice. No duty to update. Past performance is not reliable. Forward-looking statements carry risks. Methodology: questions-first framework using public sources. No conflicts. Authors do not hold positions unless stated. © 2026 LucidQuest Ventures Ltd.

Entities / Keywords

Merck; MSD; SciBrunch Therapeutics; SPR2015; KRAS G12D; KRAS(ON); molecular glue; cyclophilin A; CypA; colorectal cancer; CRC; pancreatic ductal adenocarcinoma; PDAC; NSCLC; RAS; MAPK; DUSP6; zoldonrasib; RMC-9805; VS-7375; Revolution Medicines; Verastem Oncology; TARGET-D 101; NCT06040541; precision oncology; targeted therapy; CDX; PDX; IND; Phase 1; FDA; AACR; United States; China; global licensing; oncology BD